Vegf receptor fusion proteins, their pharmaceutical compositions and therapeutic applications for the eye diseases
AssigneeChengdu Kanghong Biotechnologies Co. Ltd.
InventorMichael Dechao Yu
Life of this patent
Estimating the term…
Abstract
Vascular endothelial growth factor (VEGF) receptor fusion protein comprising Ig domain 2 of Flt-1 and Ig domains 3, or Ig domain 2 of Flt-1 and Ig domain 3 and 4 of KDR, the gene encoding the fusion protein, the pharmaceutical composition containing the fusion protein and the pharmaceutical use of the fusion protein are provided. The fusion protein can be used for treatment of eye disorders involving angiogenesis such as diabetic retinopathy.
Claims10
A VEGF receptor fusion protein selected from FP7 and FP8 having the amino acid sequences as shown in SEQ ID No. 2 and 4, respectively.
An isolated nucleotide sequence encoding the VEGF receptor fusion protein FP7 or FP8, having the DNA sequences as shown in SEQ ID No. 1 or 3, respectively.
A pharmaceutical composition used to treat eye diseases caused by abnormal angiogenesis, wherein the pharmaceutical composition comprises one or both of the VEGF receptor fusion proteins FP7 and FP8 having the amino acid sequences as shown in SEQ ID No. 2 and 4, respectively, in a pharmaceutically effective amount and optionally one or more pharmaceutically acceptable carriers.
A method for preparing a pharmaceutical composition comprising a VEGF receptor fusion protein for treating an angiogenesis related eye disease, comprising combining one or both of FP7 and FP8 with one or more fusion proteins selected from FP1, FP2, FP3, FP4, FP5, and FP6, together with a pharmaceutically acceptable carrier.
A method for treating an angiogenesis related eye disease, characterized by administration to a patient in need thereof one or both of FP7 and FP8 in combination with one or more additional VEGF receptor fusion proteins selected from the group consisting of FP1, FP2, FP3, FP4, FP5 and FP6.
Dependencies are inferred from the claim text.